Drug | Alert criteria |
---|---|
Citalopram | High doses: |
Above 40 mg/day | |
Above 20 mg/day in patients > 65 years of age | |
Above 20 mg/day in patients suffering from liver dysfunction | |
Administered in combination with other drugs that also prolong the QT interval of the electrocardiogram | |
Escitalopram | High doses (> 10 mg/day in patients > 65 years of age) |
Administered in combination with other drugs that also prolong the QT interval of the electrocardiogram | |
Aliskiren | In patients with a diagnosis of diabetes mellitus II or undergoing treatment with antidiabetic drugs |
Jointly administered with ACE inhibitors | |
Cilostazol | In patients suffering from a health problem where its use is contraindicated, i.e., cerebral haemorrhage, severe ventricular arrhythmias, or heart failure |
Or, in concomitant treatment with: | |
2 Antiplatelet agents | |
Antiplatelet + oral anticoagulant | |
Trimetazidine | In patients with a diagnosis of extrapyramidal and movement disorders |
Raloxifene or bazedoxifene | In patients suffering from any health problem where it is contraindicated, e.g., venous thromboembolism, uterine sac, endometrial cancer, or liver failure of any degree |
COXIBS | In patients suffering from any health problem where it is contraindicated, e.g., ischemic heart disease, peripheral arterial disease, cerebrovascular disease, heart failure, or inflammatory bowel disease |
Diclofenac or Aceclofenac | In patients suffering from any health problem where its use is contraindicated, e.g., ischemic heart disease, peripheral arterial disease, cerebrovascular disease, or heart failure |
Agomelatine | In patients ≥ 75 years of age |
Ivabradine | Co-administration with verapamil |
“Triple Whammy” (NSAIDs + RAS inhibitors + diuretics) | In patients ≥ 75 years of age or undergoing treatment for diabetes |
Canagliflozin | In patients suffering from a health problem in which it is necessary to be more careful due to an increased risk of amputation |